Bellevue, Switzerland

Isabelle Jeanclaude-Etter

USPTO Granted Patents = 6 

 

 

Average Co-Inventor Count = 7.7

ph-index = 1

Forward Citations = 22(Granted Patents)


Company Filing History:


Years Active: 2008-2018

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovations of Isabelle Jeanclaude-Etter

Introduction

Isabelle Jeanclaude-Etter is a prominent inventor based in Bellevue, Switzerland. She has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that modulate potassium channel activity. With a total of six patents to her name, her work has the potential to impact the treatment of various autoimmune and inflammatory diseases.

Latest Patents

One of her latest patents focuses on amine derivatives as potassium channel blockers. This invention relates to compounds that are useful in modulating potassium channel activity in cells, specifically targeting the Kv1.3 channels found in T cells. The invention also encompasses the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis. Additionally, it includes pharmaceutical compositions containing these compounds and methods for their preparation.

Career Highlights

Throughout her career, Isabelle has worked with notable companies such as Bionomics Inc. and Merck Patent GmbH. Her experience in these organizations has allowed her to refine her expertise in pharmaceutical development and patenting.

Collaborations

Isabelle has collaborated with several professionals in her field, including Pascale Gaillard and Jean-Pierre Gotteland. These collaborations have contributed to her innovative research and development efforts.

Conclusion

Isabelle Jeanclaude-Etter's work exemplifies the intersection of innovation and healthcare. Her contributions to potassium channel modulation hold promise for advancing treatments for autoimmune diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…